カテゴリー： MarketsandMarkets, 世界, 医療/バイオ

CRISPRのグローバル市場予測（～2028）：製品、サービス

◆英語タイトル：CRISPR Market by Product (Enzymes, Kits, Libraries), Services (gRNA design, Cell Line Engineering, Screening), Application (Drug Discovery & Development, Agriculture), End User (Pharma, Biotech, CROs, Research Institutes) - Global Forecast to 2028

MarketsandMarketsが発行した調査報告書（BT6746-23）◆商品コード：BT6746-23
◆発行会社（リサーチ会社）：MarketsandMarkets
◆発行日：2023年6月30日
◆ページ数：200
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：グローバル
◆産業分野：バイオ
◆販売価格オプション（消費税別）
Single User（1名様閲覧）USD4,950 ⇒換算￥742,500見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算￥997,500見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算￥1,222,500見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

MarketsandMarkets社の調査レポートでは、世界のCRISPR市場規模が2023年の34億ドルから、2028年には71億ドルへ上り、予測期間中、年平均15.6%増加すると予想されています。当レポートでは、CRISPRの世界市場を総合的に調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品・サービス別（製品、サービス）分析、用途別（創薬・開発、農業、その他）分析、エンドユーザー別（製薬・バイオテクノロジー、学術・研究機関、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況、企業情報などの内容をまとめています。並びに、当レポートには、Thermo Fisher Scientific,Inc. (US)、Merck KGaA (Germany)、Agilent Technologies,Inc. (US)、Genscript Biotech Corporation (China)、CRISPR Therapeutics AG (Switzerland)、Editas Medicine (US)、Intellia Therapeutics,Inc. (US)などの企業情報を記載しています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・世界のCRISPR市場規模：製品・サービス別
- 製品の市場規模
- サービスの市場規模
・世界のCRISPR市場規模：用途別
- 創薬・開発における市場規模
- 農業における市場規模
- その他用途における市場規模
・世界のCRISPR市場規模：エンドユーザー別
- 製薬・バイオテクノロジーにおける市場規模
- 学術・研究機関における市場規模
- その他エンドユーザーにおける市場規模
・世界のCRISPR市場規模：地域別
- 北米のCRISPR市場規模
- ヨーロッパのCRISPR市場規模
- アジア太平洋のCRISPR市場規模
- 中南米のCRISPR市場規模
- 中東・アフリカのCRISPR市場規模
・競争状況
・企業情報

“The CRISPR market is projected to reach USD 7.1 billion by 2028 from USD 3.4 billion in 2023, at a CAGR of 15.6% during the forecast period.”
The major factors driving the growth of the CRISPR market are the advancements and increasing demand gene editing technology, and rising funding and investment of government and private organizations is expected to propel the growth of the market. However, ethical and regulatory considerations are expected to restrain market growth to a certain extent.
The CRISPR market has been segmented based on product, application, end user, and region.

“By products & services, the products segment accounted for the largest share of the CRISPR market”
Based on products & services, the CRISPR market is categorized into products, and services. The products segment dominated the market in 2023, owing to rising demand for CRISPR products in gene editing technology domain. Along with this, advancements in delivery systems, increasing investment in gene editing research and the rising number of collaborations between academic institutions and pharmaceutical companies has led to a higher growth rate for products in the CRISPR market.

“By application, drug discovery & development segment accounted for the largest share in the CRISPR market”
Based on application, the CRISPR market is segmented into drug discovery and development, agriculture, and other applications. In 2023, the drug discovery & development segment accounted for a larger share of the CRISPR market. Growth in this market segment can be attributed to exceptional precision and efficiency offered by CRISPR-Cas9 in editing and manipulating genes. Along with this, growing demand for personalized medicine, and increased research and development activities in the field of CRISPR technology are contributing to its adoption in drug discovery and development.

“North America: the largest share of the CRISPR market”
North America accounted for the largest share of the CRISPR market. The large share of the North America region can be attributed to a well-established healthcare and biotechnology industry in the region, with advanced infrastructure, cutting-edge research institutions, and a strong ecosystem of biotechnology companies and CROs specializing in gene editing research. The presence of top academic institutions, and private companies in North America with dedicated gene editing research programs and expertise has contributed to the growth of the CRISPR market.

“Asia Pacific: The fastest-growing region in the CRISPR market.”
The Asia Pacific CRISPR market is projected to grow at the highest CAGR during the forecast period. This is attributed to increasing demand of personalized medicine, and advancements in sequencing technologies. Another key driver for the Asia Pacific CRISPR market is the region’s large and rapidly increasing population.

The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side- 70% and Demand Side- 30%
• By Designation: Executives – 55%, Research Scientists- 25%, and Managers – 20%
• By Country: North America- 50%, Europe- 20%, Asia Pacific- 15%, Latin America – 10%, and Middle East Africa- 5%

Prominent Players
• Thermo Fisher Scientific, Inc. (US)
• Merck KGaA (Germany)
• Agilent Technologies, Inc. (US)
• Genscript Biotech Corporation (China)
• CRISPR Therapeutics AG (Switzerland)
• Editas Medicine (US)
• Intellia Therapeutics, Inc. (US)
• Beam Therapeutics Inc. (US)
• Caribou Biosciences, Inc. (US)
• Lonza Group, Ltd. (Switzerland)
• Danaher Corporation (US)
• PerkinElmer, Inc. (US)
• Hera Biolabs (US)
• OriGene Technologies, Inc. (US)
• Cellecta, Inc. (US)
• Mammoth Biosciences, Inc. (US)
• Applied StemCell (US)
• New England Biolabs Inc. (US)
• ToolGen Inc. (South Korea)
• GeneCopoeia, Inc. (US)
• Twist Bioscience Corporation (US)
• Synthego Corporation (US)
• eGenesis (US)
• Inscripta, Inc. (US)
• Precision BioSciences, Inc. (US)

Research Coverage:
This report provides a detailed picture of the CRISPR market. It aims at estimating the size and future growth potential of the market across different segments, such as the product & services (Products(CRISPR kits & enzymes, CRISPR libraries, and other products), and services (gRNA synthesis & cell line development, CRISPR screening & validation services, and other services)), application (drug discovery & development, agriculture, and other applications), and end user (pharmaceutical and biotechnology companies, academic and research institutes, and other applications) and region (North America, Europe, Asia Pacific, Latin America, and Middle East Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall CRISPR market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.

The report provide insights on the following pointers:
• Analysis of key drivers (growing demand for CRISPR-based gene therapies, growing advancements and adoptions of CRISPR technology, and growing investment and funding from the government for CRISPR technology), restraints (technical challenges associated with CRISPR technology), opportunities (development of new vaccine and treatment of genetic diseases), and challenges (regulatory hurdles for CRISPR advancements) influencing the growth of the CRISPR market.
• Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the CRISPR market.
• Market Development: Comprehensive information about lucrative markets- the report analyses the CRISPR market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the CRISPR market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), Genscript Biotech Corporation (China) among others in the CRISPR market strategies. The report also helps stakeholders understand the pulse of the gene editing market and provides them information on key market drivers, restraints, challenges and opportunities.

❖ レポートの目次 ❖

1 INTRODUCTION 28
1.1 STUDY OBJECTIVES 28
1.2 MARKET DEFINITION 28
1.2.1 INCLUSIONS AND EXCLUSIONS 28
1.3 MARKET SCOPE 29
1.3.1 MARKETS COVERED 29
1.3.2 YEARS CONSIDERED 29
1.4 CURRENCY CONSIDERED 30
1.5 LIMITATIONS 30
1.6 STAKEHOLDERS 30
1.7 SUMMARY OF CHANGES 31
2 RESEARCH METHODOLOGY 32
2.1 RESEARCH DATA 32
FIGURE 1 RESEARCH DESIGN 32
2.1.1 SECONDARY DATA 32
2.1.2 PRIMARY DATA 33
FIGURE 2 BREAKDOWN OF PRIMARIES: CRISPR MARKET 34
2.2 MARKET ESTIMATION METHODOLOGY 34
FIGURE 3 CRISPR MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022 34
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2022 35
2.2.1 INSIGHTS FROM PRIMARY EXPERTS 36
FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 36
2.3 MARKET GROWTH RATE PROJECTIONS 37
FIGURE 6 CRISPR MARKET (SUPPLY-SIDE): CAGR PROJECTIONS 37
FIGURE 7 CRISPR MARKET (DEMAND-SIDE): GROWTH ANALYSIS OF DEMAND-SIDE DRIVERS 38
2.3.1 DATA TRIANGULATION 38
FIGURE 8 DATA TRIANGULATION METHODOLOGY 39
2.4 RESEARCH ASSUMPTIONS 39
2.5 RISK ANALYSIS 40
2.6 RECESSION IMPACT 40
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH) 40
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 40
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 40
 
3 EXECUTIVE SUMMARY 42
FIGURE 9 CRISPR MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION) 42
FIGURE 10 CRISPR MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 43
FIGURE 11 CRISPR MARKET: GEOGRAPHICAL SNAPSHOT 44
4 PREMIUM INSIGHTS 45
4.1 CRISPR MARKET OVERVIEW 45
FIGURE 12 RISING FOCUS ON CRISPR THERAPEUTICS DEVELOPMENT TO DRIVE GROWTH 45
4.2 NORTH AMERICA: CRISPR MARKET, BY APPLICATION AND COUNTRY (2023) 46
FIGURE 13 DRUG DISCOVERY AND DEVELOPMENT SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2023 46
4.3 CRISPR MARKET SHARE, BY END USER, 2023 VS. 2028 46
FIGURE 14 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD 46
5 MARKET OVERVIEW 47
5.1 INTRODUCTION 47
5.2 MARKET DYNAMICS 47
FIGURE 15 CRISPR MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 47
TABLE 4 CRISPR MARKET: IMPACT ANALYSIS 48
5.2.1 DRIVERS 48
5.2.1.1 Growing demand for CRISPR-based gene therapies 48
5.2.1.2 Advancements in CRISPR technology 49
5.2.1.3 Growing government and private investments and funding for CRISPR technology 49
TABLE 5 RECENT INVESTMENTS IN CRISPR (JANUARY 2020 TO JUNE 2023) 50
5.2.2 RESTRAINTS 50
5.2.2.1 Technical challenges associated with CRISPR technology 50
5.2.3 OPPORTUNITIES 51
5.2.3.1 Development of new vaccines and treatments for genetic diseases 51
5.2.4 CHALLENGES 51
5.2.4.1 Regulatory hurdles for CRISPR advancements 51
5.3 TECHNOLOGY ANALYSIS 52
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 54
FIGURE 16 CRISPR MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 54
5.5 SUPPLY AND VALUE CHAIN ANALYSIS 55
5.5.1 CRISPR MARKET: SUPPLY CHAIN ANALYSIS 55
FIGURE 17 CRISPR MARKET: SUPPLY CHAIN ANALYSIS 55
5.5.2 CRISPR MARKET: VALUE CHAIN ANALYSIS 56
FIGURE 18 CRISPR MARKET: VALUE CHAIN ANALYSIS 56
 
5.6 ECOSYSTEM ANALYSIS 57
FIGURE 19 CRISPR MARKET: ECOSYSTEM ANALYSIS 57
5.7 PORTER’S FIVE FORCES ANALYSIS 57
TABLE 6 CRISPR MARKET: PORTER’S FIVE FORCES ANALYSIS 57
5.7.1 THREAT OF NEW ENTRANTS 57
5.7.2 THREAT OF SUBSTITUTES 58
5.7.3 BARGAINING POWER OF BUYERS 58
5.7.4 BARGAINING POWER OF SUPPLIERS 58
5.7.5 INTENSITY OF COMPETITIVE RIVALRY 59
5.8 REGULATORY ANALYSIS 59
5.8.1 FDA APPROVALS 60
5.8.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 60
TABLE 7 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 60
TABLE 8 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 61
TABLE 9 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 62
TABLE 10 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 63
TABLE 11 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 63
5.9 PRICING ANALYSIS 64
TABLE 12 AVERAGE SELLING PRICES OF PRODUCTS OFFERED BY KEY PLAYERS 64
5.9.1 AVERAGE SELLING PRICE TREND ANALYSIS 64
5.10 PATENT ANALYSIS 65
FIGURE 20 PATENTS GRANTED FOR CRISPR TECHNOLOGY, JANUARY 2016 TO JUNE 2023 65
TABLE 13 TOP OWNERS OF CRISPR PATENTS 65
5.11 KEY CONFERENCES AND EVENTS IN 2023–2024 66
TABLE 14 CRISPR CONFERENCES (2023–2024) 66
5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 66
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 66
FIGURE 21 CRISPR MARKET: INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS 66
5.12.2 CRISPR MARKET: BUYING CRITERIA 67
FIGURE 22 KEY BUYING CRITERIA FOR END USERS 67
6 CRISPR MARKET, BY PRODUCT & SERVICE 68
6.1 INTRODUCTION 69
TABLE 15 CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 69
6.2 PRODUCTS 69
TABLE 16 CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 70
TABLE 17 CRISPR PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION) 70
TABLE 18 NORTH AMERICA: CRISPR PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 70
TABLE 19 EUROPE: CRISPR PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 71
TABLE 20 ASIA PACIFIC: CRISPR PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 71
TABLE 21 LATIN AMERICA: CRISPR PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 71
6.2.1 CRISPR ENZYMES AND KITS 72
6.2.1.1 CRISPR enzymes and kits segment dominated CRISPR products market 72
TABLE 22 CRISPR ENZYMES AND KITS MARKET, BY REGION, 2021–2028 (USD MILLION) 72
TABLE 23 NORTH AMERICA: CRISPR ENZYMES AND KITS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 72
TABLE 24 EUROPE: CRISPR ENZYMES AND KITS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 73
TABLE 25 ASIA PACIFIC: CRISPR ENZYMES AND KITS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 73
TABLE 26 LATIN AMERICA: CRISPR ENZYMES AND KITS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 73
6.2.2 CRISPR LIBRARIES 74
6.2.2.1 Increasing applications of CRISPR libraries in gene editing to drive growth 74
TABLE 27 CRISPR LIBRARIES MARKET, BY REGION, 2021–2028 (USD MILLION) 74
TABLE 28 NORTH AMERICA: CRISPR LIBRARIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 75
TABLE 29 EUROPE: CRISPR LIBRARIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 75
TABLE 30 ASIA PACIFIC: CRISPR LIBRARIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 75
TABLE 31 LATIN AMERICA: CRISPR LIBRARIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 76
6.2.3 OTHER PRODUCTS 76
TABLE 32 OTHER CRISPR PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION) 76
TABLE 33 NORTH AMERICA: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 77
TABLE 34 EUROPE: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 77
TABLE 35 ASIA PACIFIC: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 77
TABLE 36 LATIN AMERICA: OTHER CRISPR PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 78
6.3 SERVICES 78
TABLE 37 CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 79
TABLE 38 CRISPR SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 79
TABLE 39 NORTH AMERICA: CRISPR SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 79
TABLE 40 EUROPE: CRISPR SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 80
TABLE 41 ASIA PACIFIC: CRISPR SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 80
TABLE 42 LATIN AMERICA: CRISPR SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 80
6.3.1 GRNA SYNTHESIS AND CELL LINE DEVELOPMENT 81
6.3.1.1 Emerging opportunities in CRISPR gRNA synthesis and cell line development to drive growth 81
TABLE 43 GRNA SYNTHESIS AND CELL LINE DEVELOPMENT SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 81
TABLE 44 NORTH AMERICA: GRNA SYNTHESIS AND CELL LINE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 81
TABLE 45 EUROPE: GRNA SYNTHESIS AND CELL LINE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 82
TABLE 46 ASIA PACIFIC: GRNA SYNTHESIS AND CELL LINE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 82
TABLE 47 LATIN AMERICA: GRNA SYNTHESIS AND CELL LINE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 82
6.3.2 SCREENING AND VALIDATION 83
6.3.2.1 Rapid advancements in CRISPR technology to drive growth 83
TABLE 48 CRISPR SCREENING AND VALIDATION SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 83
TABLE 49 NORTH AMERICA: CRISPR SCREENING AND VALIDATION SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 83
TABLE 50 EUROPE: CRISPR SCREENING AND VALIDATION SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 84
TABLE 51 ASIA PACIFIC: CRISPR SCREENING AND VALIDATION SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 84
TABLE 52 LATIN AMERICA: CRISPR SCREENING AND VALIDATION SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 84
6.3.3 OTHER SERVICES 85
TABLE 53 OTHER CRISPR SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 85
TABLE 54 NORTH AMERICA: OTHER CRISPR SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 85
TABLE 55 EUROPE: OTHER CRISPR SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 86
TABLE 56 ASIA PACIFIC: OTHER CRISPR SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 86
TABLE 57 LATIN AMERICA: OTHER CRISPR SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 86
7 CRISPR MARKET, BY APPLICATION 87
7.1 INTRODUCTION 88
TABLE 58 CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 88
7.2 DRUG DISCOVERY AND DEVELOPMENT 88
7.2.1 ADVANCEMENTS IN GENOME EDITING TO DRIVE GROWTH 88
TABLE 59 CRISPR MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY REGION, 2021–2028 (USD MILLION) 89
TABLE 60 NORTH AMERICA: CRISPR MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 89
TABLE 61 EUROPE: CRISPR MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 90
TABLE 62 ASIA PACIFIC: CRISPR MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 90
TABLE 63 LATIN AMERICA: CRISPR MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 90
7.3 AGRICULTURE 91
7.3.1 GROWING DEMAND FOR ENHANCED CROP TRAITS TO DRIVE GROWTH 91
TABLE 64 CRISPR MARKET FOR AGRICULTURE, BY REGION, 2021–2028 (USD MILLION) 91
TABLE 65 NORTH AMERICA: CRISPR MARKET FOR AGRICULTURE, BY COUNTRY, 2021–2028 (USD MILLION) 91
TABLE 66 EUROPE: CRISPR MARKET FOR AGRICULTURE, BY COUNTRY, 2021–2028 (USD MILLION) 92
TABLE 67 ASIA PACIFIC: CRISPR MARKET FOR AGRICULTURE, BY COUNTRY, 2021–2028 (USD MILLION) 92
TABLE 68 LATIN AMERICA: CRISPR MARKET FOR AGRICULTURE, BY COUNTRY, 2021–2028 (USD MILLION) 92
7.4 OTHER APPLICATIONS 93
TABLE 69 CRISPR MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 93
TABLE 70 NORTH AMERICA: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 93
TABLE 71 EUROPE: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 94
TABLE 72 ASIA PACIFIC: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 94
TABLE 73 LATIN AMERICA: CRISPR MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 94
8 CRISPR MARKET, BY END USER 95
8.1 INTRODUCTION 96
TABLE 74 CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 96
8.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 96
8.2.1 GROWING DEMAND FOR CRISPR-BASED THERAPIES TO PROPEL GROWTH 96
TABLE 75 CRISPR MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION) 97
TABLE 76 NORTH AMERICA: CRISPR MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 77 EUROPE: CRISPR MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 78 ASIA PACIFIC: CRISPR MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 98
TABLE 79 LATIN AMERICA: CRISPR MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 98
8.3 ACADEMIC AND RESEARCH INSTITUTES 98
8.3.1 GROWING FOCUS ON DEVELOPING INNOVATIVE THERAPIES TO DRIVE GROWTH 98
TABLE 80 CRISPR MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 99
TABLE 81 NORTH AMERICA: CRISPR MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 99
TABLE 82 EUROPE: CRISPR MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 83 ASIA PACIFIC: CRISPR MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 84 LATIN AMERICA: CRISPR MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 100
8.4 OTHER END USERS 101
TABLE 85 CRISPR MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 101
TABLE 86 NORTH AMERICA: CRISPR MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 87 EUROPE: CRISPR MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 102
TABLE 88 ASIA PACIFIC: CRISPR MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 102
TABLE 89 LATIN AMERICA: CRISPR MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 102
9 CRISPR MARKET, BY REGION 103
9.1 INTRODUCTION 104
TABLE 90 CRISPR MARKET, BY REGION, 2021–2028 (USD MILLION) 104
9.2 NORTH AMERICA 104
FIGURE 23 NORTH AMERICA: CRISPR MARKET SNAPSHOT 105
TABLE 91 NORTH AMERICA: CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 106
TABLE 92 NORTH AMERICA: CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 106
TABLE 93 NORTH AMERICA: CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 106
TABLE 94 NORTH AMERICA: CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 107
TABLE 95 NORTH AMERICA: CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 107
9.2.1 US 107
9.2.1.1 Increasing demand for CRISPR products and services across various industries to drive growth 107
TABLE 96 US: CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 108
TABLE 97 US: CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 108
TABLE 98 US: CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 108
TABLE 99 US: CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 109
TABLE 100 US: CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 109
9.2.2 CANADA 109
9.2.2.1 Increasing demand for gene-editing technologies to boost growth 109
TABLE 101 CANADA: CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 110
TABLE 102 CANADA: CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 110
TABLE 103 CANADA: CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 110
TABLE 104 CANADA: CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 111
TABLE 105 CANADA: CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 111
9.2.3 NORTH AMERICA: IMPACT OF RECESSION 111
9.3 EUROPE 111
TABLE 106 EUROPE: CRISPR MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 107 EUROPE: CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 112
TABLE 108 EUROPE: CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 113
TABLE 109 EUROPE: CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 113
TABLE 110 EUROPE: CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 113
TABLE 111 EUROPE: CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 114
9.3.1 GERMANY 114
9.3.1.1 Rapidly increasing biotechnology sector to support growth 114
TABLE 112 GERMANY: CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 114
TABLE 113 GERMANY: CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 115
TABLE 114 GERMANY: CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 115
TABLE 115 GERMANY: CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 115
TABLE 116 GERMANY: CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 116
9.3.2 UK 116
9.3.2.1 Significant government investments in genomics research to propel growth 116
TABLE 117 UK: CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 116
TABLE 118 UK: CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 117
TABLE 119 UK: CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 117
TABLE 120 UK: CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 117
TABLE 121 UK: CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 118
9.3.3 FRANCE 118
9.3.3.1 Increasing demand for targeted therapies and personalized medicine to propel growth 118
TABLE 122 FRANCE: CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 119
TABLE 123 FRANCE: CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 119
TABLE 124 FRANCE: CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 119
TABLE 125 FRANCE: CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 120
TABLE 126 FRANCE: CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 120
9.3.4 ITALY 120
9.3.4.1 Increasing demand for innovative therapeutic solutions to drive growth 120
TABLE 127 ITALY: CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 121
TABLE 128 ITALY: CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 121
TABLE 129 ITALY: CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 121
TABLE 130 ITALY: CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 122
TABLE 131 ITALY: CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 122
9.3.5 SPAIN 122
9.3.5.1 Increasing demand for precision medicine to drive growth 122
TABLE 132 SPAIN: CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 123
TABLE 133 SPAIN: CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 123
TABLE 134 SPAIN: CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 123
TABLE 135 SPAIN: CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 124
TABLE 136 SPAIN: CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 124
9.3.6 REST OF EUROPE 124
TABLE 137 REST OF EUROPE: CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 125
TABLE 138 REST OF EUROPE: CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 125
TABLE 139 REST OF EUROPE: CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 125
TABLE 140 REST OF EUROPE: CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 126
TABLE 141 REST OF EUROPE: CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 126
9.3.7 EUROPE: IMPACT OF RECESSION 126
9.4 ASIA PACIFIC 127
FIGURE 24 ASIA PACIFIC: CRISPR MARKET SNAPSHOT 127
TABLE 142 ASIA PACIFIC: CRISPR MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 143 ASIA PACIFIC: CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 128
TABLE 144 ASIA PACIFIC: CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 128
TABLE 145 ASIA PACIFIC: CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 129
TABLE 146 ASIA PACIFIC: CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 129
TABLE 147 ASIA PACIFIC: CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 129
9.4.1 CHINA 130
9.4.1.1 Increasing investments in R&D to drive growth 130
TABLE 148 CHINA: CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 130
TABLE 149 CHINA: CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 131
TABLE 150 CHINA: CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 131
TABLE 151 CHINA: CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 131
TABLE 152 CHINA: CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 132
9.4.2 JAPAN 132
9.4.2.1 Potential of CRISPR-based therapies in personalized medicine to present opportunities for market growth 132
TABLE 153 JAPAN: CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 132
TABLE 154 JAPAN: CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 133
TABLE 155 JAPAN: CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 133
TABLE 156 JAPAN: CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 133
TABLE 157 JAPAN: CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 134
9.4.3 INDIA 134
9.4.3.1 Increasing prevalence of genetic disorders to support growth 134
TABLE 158 INDIA: CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 134
TABLE 159 INDIA: CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 134
TABLE 160 INDIA: CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 135
TABLE 161 INDIA: CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 135
TABLE 162 INDIA: CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 135
9.4.4 REST OF ASIA PACIFIC 136
TABLE 163 REST OF ASIA PACIFIC: CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 136
TABLE 164 REST OF ASIA PACIFIC: CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 136
TABLE 165 REST OF ASIA PACIFIC: CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 137
TABLE 166 REST OF ASIA PACIFIC: CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 137
TABLE 167 REST OF ASIA PACIFIC: CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 137
9.4.5 ASIA PACIFIC: IMPACT OF RECESSION 137
9.5 LATIN AMERICA 138
TABLE 168 LATIN AMERICA: CRISPR MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 138
TABLE 169 LATIN AMERICA: CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 139
TABLE 170 LATIN AMERICA: CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 139
TABLE 171 LATIN AMERICA: CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 139
TABLE 172 LATIN AMERICA: CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 140
TABLE 173 LATIN AMERICA: CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 140
9.5.1 BRAZIL 140
9.5.1.1 Growing adoption of genome technologies to propel growth 140
TABLE 174 BRAZIL: CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 141
TABLE 175 BRAZIL: CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 141
TABLE 176 BRAZIL: CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 141
TABLE 177 BRAZIL: CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 142
TABLE 178 BRAZIL: CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 142
9.5.2 REST OF LATIN AMERICA 142
TABLE 179 REST OF LATIN AMERICA: CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 143
TABLE 180 REST OF LATIN AMERICA: CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 143
TABLE 181 REST OF LATIN AMERICA: CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 143
TABLE 182 REST OF LATIN AMERICA: CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 144
TABLE 183 REST OF LATIN AMERICA: CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 144
9.5.3 LATIN AMERICA: IMPACT OF RECESSION 144
9.6 MIDDLE EAST & AFRICA 145
TABLE 184 MIDDLE EAST & AFRICA: CRISPR MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 145
TABLE 185 MIDDLE EAST & AFRICA: CRISPR PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 145
TABLE 186 MIDDLE EAST & AFRICA: CRISPR SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION) 146
TABLE 187 MIDDLE EAST & AFRICA: CRISPR MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 146
TABLE 188 MIDDLE EAST & AFRICA: CRISPR MARKET, BY END USER, 2021–2028 (USD MILLION) 146
9.6.1 MIDDLE EAST & AFRICA: IMPACT OF RECESSION 147
10 COMPETITIVE LANDSCAPE 148
10.1 INTRODUCTION 148
10.2 STRATEGIES ADOPTED BY KEY PLAYERS 148
FIGURE 25 CRISPR MARKET: STRATEGIES ADOPTED BY KEY PLAYERS 149
10.3 REVENUE SHARE ANALYSIS (TOP 4 PLAYERS) 149
FIGURE 26 REVENUE ANALYSIS FOR TOP 4 COMPANIES (2020−2022) 149
10.4 MARKET SHARE ANALYSIS (2022) 150
FIGURE 27 CRISPR MARKET: MARKET SHARE ANALYSIS (2022) 150
10.5 COMPANY EVALUATION MATRIX 151
FIGURE 28 CRISPR MARKET: COMPANY EVALUATION MATRIX (2022) 152
10.5.1 STARS 153
10.5.2 EMERGING LEADERS 153
10.5.3 PERVASIVE PLAYERS 153
10.5.4 PARTICIPANTS 153
10.6 COMPANY EVALUATION MATRIX: START-UPS/SMES (2022) 153
10.6.1 PROGRESSIVE COMPANIES 153
10.6.2 STARTING BLOCKS 153
10.6.3 RESPONSIVE COMPANIES 154
10.6.4 DYNAMIC COMPANIES 154
FIGURE 29 CRISPR MARKET: START-UP/SME EVALUATION MATRIX (2022) 154
10.7 COMPETITIVE BENCHMARKING 155
10.7.1 LIST OF START-UP/SME PLAYERS 155
TABLE 189 CRISPR MARKET: LIST OF START-UP/SME PLAYERS 155
10.7.2 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS 156
TABLE 190 CRISPR MARKET: COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS 156
10.8 COMPETITIVE SCENARIO AND TRENDS 157
TABLE 191 CRISPR MARKET: DEALS 157
10.8.1 PRODUCT LAUNCHES 158
TABLE 192 CRISPR MARKET: PRODUCT LAUNCHES 158
10.8.2 OTHER DEVELOPMENTS 158
TABLE 193 CRISPR MARKET: OTHER DEVELOPMENTS 158
11 COMPANY PROFILES 159
11.1 KEY PLAYERS 159
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1.1 THERMO FISHER SCIENTIFIC INC. 159
TABLE 194 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 159
11.1.2 MERCK KGAA 163
TABLE 195 MERCK KGAA: COMPANY OVERVIEW 163
FIGURE 31 MERCK KGAA: COMPANY SNAPSHOT (2022) 164
11.1.3 AGILENT TECHNOLOGIES, INC. 167
TABLE 196 AGILENT TECHNOLOGIES: COMPANY OVERVIEW 167
FIGURE 32 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2022) 168
11.1.4 GENSCRIPT 171
TABLE 197 GENSCRIPT: COMPANY OVERVIEW 171
FIGURE 33 GENSCRIPT: COMPANY SNAPSHOT (2022) 172
11.1.5 CRISPR THERAPEUTICS AG 175
TABLE 198 CRISPR THERAPEUTICS AG: COMPANY OVERVIEW 175
FIGURE 34 CRISPR THERAPEUTICS AG: COMPANY SNAPSHOT (2022) 175
11.1.6 EDITAS MEDICINE 177
TABLE 199 EDITAS MEDICINE: COMPANY OVERVIEW 177
FIGURE 35 EDITAS MEDICINE: COMPANY SNAPSHOT (2022) 177
11.1.7 INTELLIA THERAPEUTICS INC. 179
TABLE 200 INTELLIA THERAPEUTICS INC.: COMPANY OVERVIEW 179
FIGURE 36 INTELLIA THERAPEUTICS INC.: COMPANY SNAPSHOT (2022) 179
11.1.8 BEAM THERAPEUTICS, INC. 181
TABLE 201 BEAM THERAPEUTICS INC.: COMPANY OVERVIEW 181
FIGURE 37 BEAM THERAPEUTICS INC.: COMPANY SNAPSHOT (2022) 181
11.1.9 CARIBOU BIOSCIENCES 183
TABLE 202 CARIBOU BIOSCIENCES, INC.: COMPANY OVERVIEW 183
11.1.10 LONZA GROUP LTD. 184
TABLE 203 LONZA: COMPANY OVERVIEW 184
FIGURE 38 LONZA: COMPANY SNAPSHOT (2022) 185
11.1.11 DANAHER CORPORATION 187
TABLE 204 DANAHER CORPORATION: COMPANY OVERVIEW 187
FIGURE 39 DANAHER CORPORATION: COMPANY SNAPSHOT (2022) 188
11.1.12 PERKINELMER (REVVITY, INC.) 189
TABLE 205 PERKINELMER: COMPANY OVERVIEW 189
FIGURE 40 PERKINELMER: COMPANY SNAPSHOT (2022) 190
11.1.13 HERA BIOLABS 192
TABLE 206 HERA BIOLABS: COMPANY OVERVIEW 192
11.1.14 ORIGENE TECHNOLOGIES, INC. 193
TABLE 207 ORIGENE TECHNOLOGIES, INC.: COMPANY OVERVIEW 193
11.1.15 CELLECTA, INC. 194
TABLE 208 CELLECTA, INC.: COMPANY OVERVIEW 194
11.2 OTHER PLAYERS 196
11.2.1 MAMMOTH BIOSCIENCES INC. 196
11.2.2 APPLIED STEMCELL 196
11.2.3 NEW ENGLAND BIOLABS INC. 197
11.2.4 TOOLGEN INC. 197
11.2.5 GENECOPOEIA, INC. 198
11.2.6 TWIST BIOSCIENCE CORP. 198
11.2.7 SYNTHEGO CORPORATION 199
11.2.8 EGENESIS 199
11.2.9 INSCRIPTA, INC. 200
11.2.10 PRECISION BIOSCIENCES, INC. 200
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
 
12 APPENDIX 201
12.1 DISCUSSION GUIDE 201
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 204
12.3 CUSTOMIZATION OPTIONS 206
12.4 RELATED REPORTS 206
12.5 AUTHOR DETAILS 207



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ CRISPRのグローバル市場予測（～2028）：製品、サービス(CRISPR Market by Product (Enzymes, Kits, Libraries), Services (gRNA design, Cell Line Engineering, Screening), Application (Drug Discovery & Development, Agriculture), End User (Pharma, Biotech, CROs, Research Institutes) - Global Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。
グローバルリサーチ調査資料のイメージグローバルリサーチ調査資料のイメージ
◆関連リサーチレポート◆
  • ハイスループットスクリーニングのグローバル市場予測（～2028）：消耗品、機器、サービス、ソフトウェア
  • 歯科用ロボットのグローバル市場予測（～2028）：独立型ロボット、ロボット支援システム、ソフトウェア、サービス
  • テレヘルス・テレメディスン（遠隔医療）のグローバル市場予測（～2028）：ソフトウェア・サービス（RPM、リアルタイム）、ハードウェア（モニター）
  • 細胞解析のグローバル市場予測（～2028）：試薬・消耗品、機器、付属品、ソフトウェア、サービス
  • バイオ除染のグローバル市場予測（～2028）：機器、サービス、消耗品

    • ◆H&Iグローバルリサーチのお客様（例）◆